Literature DB >> 19596972

Circulating hTERT DNA in early breast cancer.

Rosa Divella1, Stefania Tommasi, Rosanna Lacalamita, Antonella Daniele, Ines Abbate, Vito Michele Garrisi, Eufemia Savino, Maria Coviello, Vincenza Rubini, Giovanni Simone, Angelo Paradiso, Michele Quaranta.   

Abstract

BACKGROUND: The objective of the study was to quantify the human telomerase reverse transcriptase (hTERT) gene in the circulating DNA of patients with primary breast cancer (BC) and to test its correlation with clinical parameters of the disease. PATIENTS AND METHODS: One hundred and twenty-one BC patients, 30 patients with fibroadenoma (NBC) and 50 healthy women were enrolled.
RESULTS: The level of hTERT in the plasma was significantly different in BC, NBC and controls (p<0.01), showing a sensitivity of 50% and specificity of 90% in the ability to detect malignancy. The circulating hTERT DNA was significantly different in the estrogen receptor (ER)(+)/progesterone receptor (PgR)(+) compared to the ER(-)/PgR(-) patients (p=0.03). Higher hTERT levels were associated with higher human epidermal growth factor receptor (HER)-2/Neu expression: score 0-1 vs. score 2+ (p=0.01) and vs. score 3+ (p=0.02). Finally, hTERT was significantly inversely correlated with the carbohydrate antigen (CA) 15.3 serum level (p=0.001).
CONCLUSION: Circulating hTERT DNA has a better diagnostic value than CA 15.3 in early breast cancer disease and could be a possible candidate as a tumor marker in patients with infiltrating ductal carcinoma positive to steroid hormonal receptor and with amplification of HER-2/Neu.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19596972

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  8 in total

Review 1.  Testing for oncogenic molecular aberrations in cell-free DNA-based liquid biopsies in the clinic: are we there yet?

Authors:  Jiri Polivka; Martin Pesta; Filip Janku
Journal:  Expert Rev Mol Diagn       Date:  2015-11-11       Impact factor: 5.225

Review 2.  The potential utility of telomere-related markers for cancer diagnosis.

Authors:  Christopher M Heaphy; Alan K Meeker
Journal:  J Cell Mol Med       Date:  2011-06       Impact factor: 5.310

Review 3.  How to Predict Metastasis in Luminal Breast Cancer? Current Solutions and Future Prospects.

Authors:  Sylwia Tabor; Małgorzata Szostakowska-Rodzos; Anna Fabisiewicz; Ewa A Grzybowska
Journal:  Int J Mol Sci       Date:  2020-11-09       Impact factor: 5.923

4.  Circulating nucleic acids in plasma and serum: diagnosis and prognosis in cancer.

Authors:  Peter Brian Gahan
Journal:  EPMA J       Date:  2010-06-09       Impact factor: 6.543

Review 5.  Telomerase as a useful target in cancer fighting-the breast cancer case.

Authors:  Hanna Holysz; Natalia Lipinska; Anna Paszel-Jaworska; Blazej Rubis
Journal:  Tumour Biol       Date:  2013-04-05

Review 6.  The clinical utilization of circulating cell free DNA (CCFDNA) in blood of cancer patients.

Authors:  Yahya I Elshimali; Husseina Khaddour; Marianna Sarkissyan; Yanyuan Wu; Jaydutt V Vadgama
Journal:  Int J Mol Sci       Date:  2013-09-13       Impact factor: 5.923

7.  Blockade of telomerase reverse transcriptase enhances chemosensitivity in head and neck cancers through inhibition of AKT/ERK signaling pathways.

Authors:  Tengda Zhao; Fengchun Hu; Xingguang Liu; Qian Tao
Journal:  Oncotarget       Date:  2015-11-03

Review 8.  Liquid biopsy prediction of axillary lymph node metastasis, cancer recurrence, and patient survival in breast cancer: A meta-analysis.

Authors:  Ju-Han Lee; Hoiseon Jeong; Jung-Woo Choi; Hwa Eun Oh; Young-Sik Kim
Journal:  Medicine (Baltimore)       Date:  2018-10       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.